Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 2/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.45 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 3/20 | 0.43 |
| ▸ | DRD3 | P35462 | 6/20 | 0.41 |
| ▸ | DRD2 | P14416 | 5/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | HTR7 | P34969 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5077332 | 0.96 | AURKA (0.58) | AURKAAURKBHRH3DHODHHTR2A | |
| SCHEMBL5140690 | 0.91 | DHODH (0.47) | AURKAAURKBHRH3DHODHHTR2A | |
| SCHEMBL5074072 | 0.91 | AURKA (0.50) | AURKAAURKBHRH3DHODHHTR2A | |
| SCHEMBL5253308 | 0.87 | HRH3 (0.45) | AURKAAURKBHRH3HTR2ADRD3 | |
| SCHEMBL5076308 | 0.87 | DHODH (0.50) | AURKAAURKBHRH3DHODHHTR2A | |
| SCHEMBL5074076 | 0.86 | CHEK1 (0.49) | HRH3DHODHHTR2ACREBBPKDM4E | |
| SCHEMBL5077273 | 0.85 | DHODH (0.49) | AURKAAURKBDHODHHTR2AKDM4E | |
| SCHEMBL5076357 | 0.84 | DHODH (0.53) | HRH3DHODHHTR2ACREBBPKDM4E | |
| SCHEMBL5251170 | 0.83 | DRD2 (0.47) | AURKAAURKBHRH3HTR2ADRD3 | |
| SCHEMBL5076369 | 0.81 | DHODH (0.53) | AURKAAURKBDHODHHTR2AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008154129-A1 | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING, REDUCING, AMELIORATING, ALLEVIATING, OR PREVENTING DRY EYE | BAUSCH & LOMB INCORPORATED (US) | 2008-12-18 | — | — | WO | claimed |
| US-20080305994-A1 | Pharmaceutical Compositions and Method for Treating, Reducing, Ameliorating, Alleviating, or Preventing Dry Eye | BAUSCH & LOMB INCORPORATED | 2008-12-11 | — | — | US | claimed |
| WO-2008154129-A1 | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING, REDUCING, AMELIORATING, ALLEVIATING, OR PREVENTING DRY EYE | BAUSCH & LOMB INCORPORATED (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20080305994-A1 | Pharmaceutical Compositions and Method for Treating, Reducing, Ameliorating, Alleviating, or Preventing Dry Eye | BAUSCH & LOMB INCORPORATED | 2008-12-11 | — | — | US | disclosed |
| US-7041675-B2 | Heterocyclic compounds and their use as PARP inhibitors | ABBOTT GMBH & CO. KG (DE) | 2006-05-09 | — | — | US | disclosed |
| US-20030134843-A1 | Heterocyclic compounds and their use as parp inhibitors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305994-A1 | Pharmaceutical Compositions and Method for Treating, Reducing, Ameliorating, Alleviating, or Preventing Dry Eye | PARP1, PARP2, PARP12 | AURKA 3231/4885AURKB 2091/4885HRH3 625/4885 |
| US-20030134843-A1 | Heterocyclic compounds and their use as parp inhibitors | PARP1, PARP2, PARP11 | AURKA 1972/4885AURKB 1525/4885HRH3 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.